Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
作者信息
Zequi Stênio C
机构信息
A. C. Camargo Cancer Center, Fundação Prudente, São Paulo, SP, Brasil.
出版信息
Int Braz J Urol. 2020 May-Jun;46(3):476. doi: 10.1590/S1677-5538.IBJU.2020.03.12.
Abstract
摘要
相似文献
1
Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.编者按：接受舒尼替尼治疗的同步转移性肾细胞癌患者中即刻与延迟减瘤性肾切除术的比较：SURTIME随机临床试验
Int Braz J Urol. 2020 May-Jun;46(3):476. doi: 10.1590/S1677-5538.IBJU.2020.03.12.
2
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.细胞减灭性肾切除术和舒尼替尼暴露 - 马来酸舒尼替尼治疗转移性肾细胞癌患者的即时手术或手术后（SURTIME）试验的事后分析。
BJU Int. 2022 Jul;130(1):68-75. doi: 10.1111/bju.15625. Epub 2021 Nov 24.
3
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).舒尼替尼治疗后的细胞减灭性肾切除术的手术安全性：即时与延迟肾切除术（SURTIME）多中心随机对照试验的结果。
Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.
4
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.舒尼替尼治疗同步转移性肾细胞癌患者中即刻与延迟细胞减瘤性肾切除术的比较：SURTIME 随机临床试验。
JAMA Oncol. 2019 Feb 1;5(2):164-170. doi: 10.1001/jamaoncol.2018.5543.
5
The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.细胞减灭性肾切除术在转移性肾细胞癌中的不断演变的角色。
Curr Opin Urol. 2019 Sep;29(5):507-512. doi: 10.1097/MOU.0000000000000657.
6
Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives.细胞减灭性肾切除术和转移性肾细胞癌：现状和未来展望。
Medicina (Kaunas). 2023 Apr 15;59(4):767. doi: 10.3390/medicina59040767.
7
Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.舒尼替尼与减瘤性肾切除术治疗转移性肾细胞癌
J Urol. 2019 Mar;201(3):453-454. doi: 10.1016/j.juro.2018.09.050.
8
Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.减瘤性肾切除术的时代已经结束了吗？：对《舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌》的评论
Urology. 2018 Nov;121:1-2. doi: 10.1016/j.urology.2018.07.007. Epub 2018 Aug 2.
9
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.多中心随机对照试验：在接受检查点抑制剂治疗的同步转移性肾细胞癌中延迟细胞减灭性肾切除术：北欧-太阳试验。
BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3.
10
Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?回复：阿诺·梅让、阿兰·拉沃德、西蒙·泰泽纳斯等。舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌。《新英格兰医学杂志》2018年；379:417 - 27：CARMENA试验：这是否意味着透明细胞肾细胞癌患者减瘤性肾切除术的终结？
Eur Urol Oncol. 2019 May;2(3):340-341. doi: 10.1016/j.euo.2018.08.002. Epub 2018 Aug 24.
Zotero 插件